Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study are:
- Determine the safety and maximum tolerated dose (MTD) of IPI-504 in GIST and STS
patients who have failed prior therapies
- Recommend a dose for subsequent studies of IPI-504